Rajan Patel, MD
Interventional Cardiology · New Orleans, LANPI 1699851071
Payments from drug & device makers
Across 683 payments — averaging $926.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$425K
- Boston Scientific$63K
- Livanova USA, Inc.$44K
- Abbott$34K
- CSL Behring$30K
- Surmodics, Inc.$26K
- plus $11K from 31 others
Across 3 payments — averaging $110.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$333
What the payments were for
- Consulting fees$27,4505%
- Speaking & faculty fees$398,26077%
- Travel & lodging$66,06913%
- Food & beverage$25,5725%
- Education$360%
- Entertainment$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 361 | $425,057 |
| Boston Scientific | 73 | $63,384 |
| Livanova USA, Inc. | 52 | $44,413 |
| Abbott | 24 | $34,142 |
| CSL Behring | 18 | $29,512 |
| Surmodics, Inc. | 19 | $25,503 |
| Medtronic(2 entities) | 47 | $3,243 |
| Canon Medical Systems USA, Inc. | 2 | $1,524 |
| Shockwave Medical, Inc | 10 | $1,427 |
| Philips North America LLC | 8 | $659 |
| Saranas, Inc. | 8 | $513 |
| Teleflex LLC | 2 | $286 |
| W. L. Gore & Associates, Inc. | 2 | $278 |
| Novo Nordisk | 3 | $265 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $259 |
| Siemens Medical Solutions USA, Inc. | 4 | $249 |
| Corindus Inc. | 1 | $224 |
| Acist Medical Systems, Inc. | 2 | $205 |
| Inari Medical, Inc. | 3 | $191 |
| AstraZeneca | 9 | $188 |
| Bard Peripheral Vascular, Inc. | 2 | $167 |
| Cardiva Medical, Inc. | 1 | $125 |
| Veryan Medical Incorporated | 1 | $116 |
| Penumbra, Inc. | 1 | $113 |
| Novartis | 4 | $83 |
| Johnson & Johnson | 5 | $82 |
| Amgen | 4 | $74 |
| Angiodynamics, Inc. | 1 | $51 |
| Edwards Lifesciences | 2 | $49 |
| Heartflow, Inc. | 1 | $44 |
| Pfizer | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Verge Medical, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Argon Medical Devices, Inc. | 1 | $13 |
| Acutus Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$385,797
- GENERAL VASCULAR ACCESS$22,474
- TandemLife$22,350
- LifeSPARC$16,440
- LifeSPARC System$3,560
- GENERAL - THERAPIES$2,817
- INTERVENTIONAL ANGIOGRAPHY SYSTEM$1,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,063
- SYNERGY$853
- OPTICROSS$800
- SYMPLICITY G3$741
- TandemHeart$536
- Resolute$455
- CorPath GRX$340
- Vascular Lithotripsy$284
- GORE CARDIOFORM Septal Occluder$278
- RESOLUTE ONYX$253
- COROFLOW$232
- FlowTriever$170
- ClotTriever$170
How this compares
$632,548 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 37 | $15,525 |
| EntrestoSacubitril/Valsartan | 11 | $8,905 |
| Ranolazine ErRanolazine | 66 | $2,823 |
| ClopidogrelClopidogrel Bisulfate | 280 | $2,293 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 161 | $1,502 |
| Prasugrel Hcl | 20 | $1,400 |
| Nitroglycerin | 47 | $1,077 |
| Atorvastatin Calcium | 99 | $781 |
| Ezetimibe | 34 | $642 |
| Metoprolol Succinate | 41 | $350 |
| Losartan Potassium | 33 | $306 |
| Carvedilol | 57 | $297 |
| Rosuvastatin Calcium | 49 | $252 |
| Nitroglycerin PatchNitroglycerin | 12 | $217 |
| Amlodipine Besylate | 41 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $188 | $15,52537 claims |
| NovartisEntresto | $83 | $8,90511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in New Orleans
- Stephen RameeNew Orleans$1.5M
- James JenkinsNew Orleans$1.2M
- Jose Tafur SotoNew Orleans$419K
- Anand IrimpenNew Orleans$100K
- George YousefNew Orleans$99K
- Jose WileyNew Orleans$77K
- Murtuza AliNew Orleans$65K
- Madhur RobertsNew Orleans$28K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.